PolarityTE, Inc. engages in the regenerative medicine and tissue engineering platform. The firm seeks to develop and obtain regulatory approval for technology that will utilize a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. Its products include SkinTE, OsteoTE, AngioTE, MyoTE, CartTe, AdiposeTE, and NeuralTE. The company was founded in 2004 and is headquartered in Salt Lake City, UT.
Industry, Sector and Symbol
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
Phone385-237-2279
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees33
OptionableOptionable
Polarityte (NASDAQ:COOL) Frequently Asked Questions
What is Polarityte's stock symbol?
Polarityte trades on the NASDAQ under the ticker symbol "COOL."
How were Polarityte's earnings last quarter?
Polarityte Inc (NASDAQ:COOL) issued its quarterly earnings results on Wednesday, September, 12th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.26. The firm earned $0.42 million during the quarter. View Polarityte's Earnings History.
When is Polarityte's next earnings date?
What price target have analysts set for COOL?
1 Wall Street analysts have issued 12 month price objectives for Polarityte's shares. Their forecasts range from $65.00 to $65.00. On average, they expect Polarityte's stock price to reach $65.00 in the next year. This suggests a possible upside of 275.1% from the stock's current price. View Analyst Price Targets for Polarityte.
What is the consensus analysts' recommendation for Polarityte?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Polarityte in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Polarityte.
What are Wall Street analysts saying about Polarityte stock?
Here are some recent quotes from research analysts about Polarityte stock:
- 1. According to Zacks Investment Research, "PolarityTE, Inc. creates regenerative medicine and provides tissue engineering platform. It develops and obtains regulatory approval for technology which utilizes a patient's own tissue substrates for regeneration of skin, bone, muscle, cartilage and nerves. The product pipeline comprises SkinTE, OsteoTE, AngioTE, MyoTE, CarteTE, AdiposeTE and NeuralTE. PolarityTE, Inc., formerly known as Majesco Entertainment Company, is headquatered in Salt lake City, Utah. " (8/27/2018)
- 2. Cantor Fitzgerald analysts commented, "We believe that PolarityTE can revolutionize the field of regenerative medicine. We think SkinTE can achieve over $600 million revenue from the currently built out facility, with perhaps multiples of this number when adding bone, cartilage, heart and muscle products in development. $65/sh price target is derived from the combined risk-adjusted NPV of the future cash flows from the SkinTE product and an enterprise value for the follow-on product lines." (7/25/2018)
Has Polarityte been receiving favorable news coverage?
Headlines about COOL stock have trended very positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Polarityte earned a media sentiment score of 3.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
Who are some of Polarityte's key competitors?
Who are Polarityte's key executives?
Polarityte's management team includes the folowing people:
- Denver M. Lough, Chairman, President, Chief Executive Officer & CSO
- Edward Swanson, Chief Operating Officer & Executive Vice President
- Paul Mann, Chief Financial Officer
- Michael W. Neumeister, Chief Medical Officer
- Stephen Milner, Chief Clinical Officer
Who are Polarityte's major shareholders?
Polarityte's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Comprehensive Portfolio Management LLC (0.00%). Company insiders that own Polarityte stock include Barry C Honig, Edward Winslow Swanson, Jeffrey Hansen Dyer, John Stetson, Michael Martin Beeghley, Paul Elliot Mann and Peter A Cohen. View Institutional Ownership Trends for Polarityte.
Which major investors are selling Polarityte stock?
How do I buy shares of Polarityte?
Shares of COOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Polarityte's stock price today?
One share of COOL stock can currently be purchased for approximately $17.33.
What is Polarityte's official website?
How can I contact Polarityte?
Polarityte's mailing address is 1960 S 4250 W, SALT LAKE CITY UT, 84104. The company can be reached via phone at 385-237-2279 or via email at [email protected]
MarketBeat Community Rating for Polarityte (NASDAQ COOL)
MarketBeat's community ratings are surveys of what our community members think about Polarityte and other stocks. Vote "Outperform" if you believe COOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
